Document is current
Any future updates will be listed below
-
Authors
Cooper, Samuel E. https://orcid.org/0000-0001-9563-1750
Keller, Nicole E. https://orcid.org/0000-0002-0259-6720
Bauer, Elizabeth A.
Lambert, Sydney R.
Hennings, Augustin C.
Azar, Ameera A.
Bibb, Sophia A.
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
Cisler, Josh M.
Lewis-Peacock, Jarrod A. https://orcid.org/0000-0002-9918-465X
Dunsmoor, Joseph E. https://orcid.org/0000-0002-5448-6873
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH138889)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32 MH106454)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH119132)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R33 MH108753)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH117293)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH125886)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH129042)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA030740)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA030038)
- License Information
-
More Information
Article History
Received: 18 November 2025
Revised: 4 February 2026
Accepted: 6 March 2026
First Online: 23 April 2026
Competing interests
: Charles Nemeroff is a consultant for Engrail Therapeutics, Clexio Biosciences LTD, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Denovo Biopharma, Alvogen, Acadia Pharmaceuticals, Inc, Reunion Neuroscience, Kivira Health, Inc, and Neurocrine Biosciences, LLC. CBN owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). CBN owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Signant Health, Galen Mental Health LLC, Kivira Health, Inc., and Senseye Inc. All other authors declare no conflicts of interests.
: All study procedures were performed in accordance with relevant guidelines and regulations. The study protocol was approved by the Institutional Review Board at The University of Texas at Austin (IRB #2017-02-0094). Written informed consent was obtained from all participants prior to participation.
